Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.42 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | PGD | P52209 | 3/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15570481 | 0.80 | HCAR2 (0.56) | HCAR2 | |
| SCHEMBL4439679 | 0.80 | HCAR2 (0.56) | HCAR2 | |
| SCHEMBL29571379 | 0.80 | S1PR1 (0.44) | S1PR1PGK1PGK2PGDMPI | |
| Fumaric Acid SCHEMBL3889386 | 0.76 | PGK1 (0.50) | PGK1PGK2PGDMPILPAR3 | |
| SCHEMBL8459558 | 0.74 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL6049911 | 0.74 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL6049907 | 0.74 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL7328567 | 0.74 | PGD (0.58) | S1PR1PGK1PGK2PGDLPAR3 | |
| SCHEMBL2045541 | 0.74 | HCAR2 (0.48) | HCAR2 | |
| SCHEMBL30211348 | 0.72 | S1PR1 (0.64) | S1PR1LPAR3LPAR1ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| CN-101410407-A | Substituted adenines and the uses thereof | ASTRAZENECA AB (SE) | 2009-04-15 | — | — | CN | disclosed |
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| EP-2010553-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008117047-A1 | PYRAZOLO[3, 4-D]PYRIMIDINE DERIVATIVES AS ANTIBACTERIAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117046-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES AS ANTIBACTERIAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| CN-101072787-A | Substituted adenines and the use thereof | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | CN | disclosed |
| WO-2007113538-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
| EP-1805196-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | AstraZeneca AB (SE) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006040558-A1 | SUBSTITUTED ADENINES AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | S1PR1 2196/4885HCAR2 1093/4885PGK1 1416/4885 |
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | S1PR1 2319/4885HCAR2 1156/4885PGK1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.